Small New Jersey firm pushes further into sterile injectables


New Jersey-based Teligent, a small specialty generic pharmaceutical company, will expand its manufacturing facility, giving it the capacity to quadruple its production.

The company will spend about $50 million to add 110,000 of space to its facility in the Atlantic City area. Peter Gallagher, Teligent’s vice president of strategic affairs, told the the press of Atlantic City, that the company expects the project to be complete next year, allowing it to double employment to about 200 people by 2018.  

Teligent will expand packaging and production, including adding a  sterile injectable manufacturing suite. The company last fall bought Canada-based Alveda Pharmaceuticals for $35.4 million, moving into the sterile injectables market in Canada.  


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Teligent reported 2015 revenues of $44.3 million.

- read the press of Atlantic City story

Related Articles: 
Pfizer building modular biologics plant in China
UPDATED: Pfizer closing Hospira plant in Colorado, 100 jobs to be lost

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.